Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.

Academic Article


  • We report a consecutive series of 59 patients with MDS who underwent reduced-intensity hematopoietic stem cell transplantation (RI-HSCT) with fludarabine/melphalan conditioning and tacrolimus/sirolimus-based GVHD prophylaxis. Two-year OS, EFS, and relapse incidences were 75.1%, 65.2%, and 20.9%, respectively. The cumulative incidence of non-relapse mortality at 100 days, 1 year, and 2 years was 3.4%, 8.5%, and 10.5%, respectively. The incidence of grade II-IV acute GVHD was 35.4%; grade III-IV was 18.6%. Forty of 55 evaluable patients developed chronic GVHD; of these 35 were extensive grade. This RI-HSCT protocol produces encouraging outcomes in MDS patients, and tacrolimus/sirolimus-based GVHD prophylaxis may contribute to that promising result.
  • Published In

  • Leukemia Research  Journal
  • Keywords

  • Adult, Aged, Chemoprevention, Dose-Response Relationship, Drug, Drug Combinations, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Male, Melphalan, Middle Aged, Myelodysplastic Syndromes, Retrospective Studies, Sirolimus, Survival Analysis, Tacrolimus, Transplantation Conditioning, Transplantation, Homologous, Vidarabine, Young Adult
  • Digital Object Identifier (doi)

    Author List

  • Nakamura R; Palmer JM; O'Donnell MR; Stiller T; Thomas SH; Chao J; Alvarnas J; Parker PM; Pullarkat V; Maegawa R
  • Start Page

  • 1152
  • End Page

  • 1156
  • Volume

  • 36
  • Issue

  • 9